KLAIL, Tomáš, Petra ŠEDOVÁ, Jan VINKLÁREK, Ingrid KOVACOVA, Michal BAR, Filip CIHLAR, David CERNIK, Lubomir KOCI, René JURA, Roman HERZIG, Jakub HUSTÝ, Martin KOCHER, Martin KOVAR, Miroslava NEVSIMALOVA, Jan RAUPACH, Miloslav ROCEK, Daniel SANAK, Petr SEVCIK, David SKOLOUDIK, Martin SRAMEK, Jiří VANÍČEK, Peter VASKO, Daniel VACLAVIK, Ales TOMEK and Robert MIKULÍK. Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy. Journal of vascular and interventional radiology. New York: ELSEVIER, 2023, vol. 34, No 9, p. "1502"-"1512.e12", 21 pp. ISSN 1051-0443. Available from: https://dx.doi.org/10.1016/j.jvir.2023.05.017.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy
Authors KLAIL, Tomáš (203 Czech Republic, belonging to the institution), Petra ŠEDOVÁ (203 Czech Republic, belonging to the institution), Jan VINKLÁREK (203 Czech Republic, belonging to the institution), Ingrid KOVACOVA (203 Czech Republic), Michal BAR (203 Czech Republic), Filip CIHLAR (203 Czech Republic), David CERNIK (203 Czech Republic), Lubomir KOCI (203 Czech Republic), René JURA (203 Czech Republic, belonging to the institution), Roman HERZIG (203 Czech Republic), Jakub HUSTÝ (203 Czech Republic, belonging to the institution), Martin KOCHER (203 Czech Republic), Martin KOVAR (203 Czech Republic), Miroslava NEVSIMALOVA (203 Czech Republic), Jan RAUPACH (203 Czech Republic), Miloslav ROCEK (203 Czech Republic), Daniel SANAK (203 Czech Republic), Petr SEVCIK (203 Czech Republic), David SKOLOUDIK (203 Czech Republic), Martin SRAMEK (203 Czech Republic), Jiří VANÍČEK (203 Czech Republic, belonging to the institution), Peter VASKO (203 Czech Republic), Daniel VACLAVIK (203 Czech Republic), Ales TOMEK (203 Czech Republic) and Robert MIKULÍK (203 Czech Republic, guarantor, belonging to the institution).
Edition Journal of vascular and interventional radiology, New York, ELSEVIER, 2023, 1051-0443.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.900 in 2022
RIV identification code RIV/00216224:14110/23:00131949
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.jvir.2023.05.017
UT WoS 001068364800001
Keywords (in Czech) THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES
Keywords in English THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES
Tags 14110119, 14110127, 14110132, 14110211, 14110216, Excelence Science, FNUSA, MU, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/4/2024 08:50.
Abstract
Purpose: To investigate the safety and efficacy of baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT). Materials and Methods: Baseline use of antiplatelet medication before MT for (AIS) may provide benefit on reperfusion and clinical outcome but could also carry an increased risk of intracranial hemorrhage (ICH). All consecutive patients with AIS and treated with MT with and without intravenous thrombolysis (IVT) between January 2012 and December 2019 in all centers performing MT nationwide were reviewed. Data were prospectively collected in national registries (eg, SITS-TBY and RES-Q). Primary outcome was functional independence (modified Rankin Scale 0-2) at 3 months; secondary outcome was ICH. Results: Of the 4,351 patients who underwent MT, 1,750 (40%) and 666 (15%) were excluded owing to missing data from the functional independence and ICH outcome cohorts, respectively. In the functional independence cohort (n = 2,601), 771 (30%) patients received antiplatelets before MT. Favorable outcome did not differ in any antiplatelet, aspirin, and clopidogrel groups when compared with that in the no-antiplatelet group: odds ratio (OR), 1.00 (95% CI, 0.84-1.20); OR, 1.05 (95% CI, 0.86-1.27); and OR, 0.88 (95% CI, 0.55-1.41), respectively. In the ICH cohort (n = 3,685), 1095 (30%) patients received antiplatelets before MT. The rates of ICH did not increase in any treatment options (any antiplatelet, aspirin, clopidogrel, and dual antiplatelet groups) when compared with those in the no-antiplatelet group: OR, 1.03 (95% CI, 0.87-1.21); OR, 0.99 (95% CI, 0.83-1.18); OR, 1.10 (95% CI, 0.82-1.47); and OR, 1.43 (95% CI, 0.87-2.33), respectively. Conclusions: Antiplatelet monotherapy before MT did not improve functional independence or increase the risk of ICH.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 31/5/2024 12:58